Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes

Annals of Transplantation

Volumn 17, Issue 2, 2012, Pages 53-61

  Nozynski, Jerzy ^a   Zakliczynski, Michael ^a   Konecka Mrowka, Dominika ^a   Zielinska, Teresa ^a   Zakliczynska, Helena ^a   Nikiel, Barbara ^b   Mlynarczyk Liszka, Joanna ^b   Mrowka, Andrzej ^a   Zembala Nozynska, Ewa ^b   Pijet, Marta ^a   Rdzanowska, Kinga ^a   Lange, Dariusz ^b   Przybylski, Roman ^a   Zembala, Marian ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Advanced glycation end products; Diabetes; Heart failure

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ARTICLE; AUTOPSY; BODY MASS; CELL METABOLISM; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HEART FAILURE; HEART MUSCLE CELL; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGAN DONOR;

EID: 84863543331     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/aot.883223     Document Type: Article

References (31)

1. Hartog JW, Voors AA, Schalkwijk CG et al: Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J, 2007; 28: 2879-85
2. Hartog JW, Hummel YM, Voors AA et al: Skinautofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail, 2008; 14: 596-602
3. Hartog JW, van de Wal RM, Schalkwijk CG et al: Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. Eur J Heart Fail, 2010; 12: 397-403
4. Willemsen S, Hartog JW, Hummel YM et al: Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur J Heart Fail, 2011; 13: 76-82
5. Nozyński J, Zakliczyński M, Konecka-Mrówka D et al: Advanced glycation end products in the development of ischemic and dilated cardiomyopathy in patients with diabetes mellitus type 2. Transplant Proc, 2009; 41: 99-104
6. Felker GM, Shaw LK, O'Connor CM: A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol, 2002; 39: 210-18
7. Maisch B, Richter A, Sandmöller A, Portig I, Pankuweit S, BMBF-Heart Failure Network: Inflammatory dilated cardiomyopathy (DCMI). Herz, 2005; 30: 535-44
8. Maron BJ, Towbin JA, Thiene G et al: Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation, 2006; 113: 1807-16
9. Basso C, Burke M, Fornes P et al: Association for European Cardiovascular Pathology: Guidelines for autopsy investigation of sudden cardiac death. Virchows Arch, 2008; 452: 11-18
10. Harris SB, Glazier RH, Tompkins JW et al: Investigating concordance in diabetes diagnosis between primary care charts (electronic medical records) and health administrative data: a retrospective cohort study. BMC Health Serv Res, 2010; 10: 347
11. Warrens MJ: Inequalities between multi-rater kappas. Adv Data Anal Classif, 2010; 4: 271-86
12. Nozyński J, Zakliczyński M, Konecka-Mrówka D et al: Advanced glycation end-products in myocardium-supported vessels: effects of heart failure and diabetes mellitus. J Heart Lung Transplant, 2011; 30: 558-64
13. Tanji N, Markowitz GS, Fu C et al: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol, 2000; 11: 1656-66
14. Schalkwijk CG, Baidoshvili A, Stehouwer CD et al: Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta, 2004; 1636: 82-89
15. Donaldson C, Taatjes DJ, Zile M et al: Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem Cell Biol, 2010; 134: 23-30
16. Ling X, Sakashita N, Takeya M et al: Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues. Lab Invest, 1998; 78: 1591-606
17. Ling X, Nagai R, Sakashita N et al: Immunohistochemial distribution and quantitative biochemical detection of advanced glycation end products in fetal to adult rats with streptozotocin-induced diabetes. Lab Invest, 2001; 81: 845-61
18. Kanauchi M, Tsujimoto N, Hashimoto T: Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care, 2001; 24: 1620-23
19. Semba RD, Najjar SS, Sun K et al: Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens, 2009; 22: 74-79
20. Zoellner H, Siddiqui S, Kelly E, Medbury H: The anti-apoptotic activity of albumin for endothelium is inhibited by advanced glycation end products restricting intramolecular movement. Cell Mol Biol Lett, 2009; 14: 575-86
21. Li SY, Sigmon VK, Babcock SA, Ren J: Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sci, 2007; 80: 1051-56
22. Ryter SW, Lee SJ, Smith A, Choi AMK: Autophagy in vascular disease. Proc Am Thorac Soc, 2010; 7: 40-47
23. Kang R, Tang D, Lotze MT, Zeh HJ: RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy, 2011; 7: 442-44
24. Liu J, Masurekar MR, Vatner DE et al: Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol, 2003; 285: H2587-91
25. Patschan S, Goligorsky MS: Autophagy: The missing link between non-enzymatically glycated proteins inducing apoptosis and premature senescence of endothelial cells? Autophagy, 2008; 16: 521-23
26. Kostin S, Pool L, Elsässer A et al: Myocytes die by multiple mechanisms in failing human hearts. Circ Res, 2003; 92: 715-24
27. Little WC, Zile MR, Kitzman DW et al: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail, 2005; 11: 191-95
28. Hartog JW, Willemsen S, van Veldhuisen DJ et al.; BENEFICIAL investigators: Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail, 2011; 13: 899-908
29. Daneshvar DA, Czer LS, Phan A et al: Heart transplantation in the elderly: why cardiac transplantation does not need to be limited to younger patients but can be safely performed in patients above 65 years of age. Ann Transplant, 2010; 15: 110-19
30. Przybylowski P, Malyszko J, Malyszko J: Chronic kidney disease in prevalent orthotopic heart transplant recipients using a new CKD-EPI formula. Ann Transplant, 2010; 15: 32-35
31. Lizak MK, Zakliczyński M, Jarosz A et al: Restrictive pattern in spirometry as a predictor of poor survival in chronic heart failure patients on betaceptor-antagonist, with possible indications for heart transplantation. Ann Transplant, 2011; 16: 16-24